The earnings call was overall positive, with significant progress reported in clinical trials and pipeline expansion. Financial management shows a strong cash position, although there are challenges related to market education and cash flow reduction.

Company Guidance

During the Amylyx Pharmaceuticals Second Quarter 2025 earnings call, guidance was provided on several key metrics and timelines. The company plans to complete recruitment for the Phase III LUCIDITY trial of Avexitide by the end of 2025, with top-line data expected in the first half of 2026. The trial focuses on post-bariatric hypoglycemia, a condition affecting an estimated 160,000 individuals in the U.S. Additionally, the company anticipates top-line data from the Phase IIb portion of the ORION trial for progressive supranuclear palsy (PSP) this quarter, a condition affecting approximately 23,000 people in the U.S. Amylyx also expects early cohort data from the Phase I LUMINA trial of AMX0114, targeting amyotrophic lateral sclerosis, by the end of the year. Financially, the company reported a cash position of $180.8 million at the end of Q2, with operating expenses of $42.9 million, and anticipates a cash runway through the end of 2026.

Progress in Avexitide Clinical Trials

The Phase III LUCIDITY trial for Avexitide is underway, with recruitment expected to be completed by year-end and data expected in the first half of 2026.

Strong Financial Position

The company ended the second quarter with $180.8 million in cash, down from $204.1 million, but sufficient to fund operations through 2026.

Pipeline Expansion

AMX0114 received Fast Track designation from the FDA and is progressing in the Phase I LUMINA trial for ALS.

Phase IIb/III ORION Trial for AMX0035

The trial is ongoing for progressive supranuclear palsy, with top-line data expected this quarter.

Reduction in Operating Expenses

Operating expenses were significantly reduced by 43% compared to the same period in 2024.

Amylyx Pharmaceuticals Inc (AMLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.46 / -	-1.07	―	―	―
Aug 07, 2025	2025 (Q2)	-0.44 / -0.46	-1.07	57.01% (+0.61)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.42	-1.75	76.00% (+1.33)	―
Mar 04, 2025	2024 (Q4)	-0.52 / -0.55	0.07	-885.71% (-0.62)	―
Nov 07, 2024	2024 (Q3)	-0.70 / -1.07	0.3	-456.67% (-1.37)	―
Aug 08, 2024	2024 (Q2)	-0.73 / -1.07	0.31	-445.16% (-1.38)	―
May 09, 2024	2024 (Q1)	>-0.01 / -1.75	0.02	-8850.00% (-1.77)	―
Feb 22, 2024	2023 (Q4)	0.23 / 0.07	-0.65	110.77% (+0.72)	―
Nov 09, 2023	2023 (Q3)	0.44 / 0.30	-0.92	132.61% (+1.22)	―
Aug 10, 2023	2023 (Q2)	0.19 / 0.31	-0.93	133.33% (+1.24)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$8.19	$7.84	-4.27%
May 08, 2025	$4.87	$4.58	-5.95%
Mar 04, 2025	$3.00	$3.01	+0.33%
Nov 07, 2024	$6.22	$6.54	+5.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.